Skip to main content
OpenTrials
Completed

NCT Number: NCT00235157

A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.

The primary objective of this study is to compare the safety and performance of the Palmaz Genesis™ balloon expandable stent, with or without sirolimus coating in the treatment of renal artery stenosis, measured at 6 months follow up via angiography.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hopital Européen Georges Pompidou, Paris, France

Loading trial locations.

About this study

Multi-center, prospective, controlled, non-randomized investigational feasibility study. One hundred (100) patients with de novo or restenotic renal artery lesions consisting of >= 50% stenosis and reference vessel of >= 4.0 to <= 8.0 mm in diameter will be sequentially included, 50 without sirolimus coating, followed by 50 with sirolimus coating Palmaz GenesisTM. Patients will be followed for 24 months post-procedure, with all patients having clinical assessments at discharge, 1,6, 12 and 24 months. This study will be conducted at twelve investigational sites.

It is anticipated that the total length of time required to complete the study will be 46 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical indication for renal artery revascularization of atherosclerotic renal artery stenosis >=50% as measured by operator or estimated original vessel diameter, based on healthy vessel segment and contralateral side.
  • The reference vessel renal artery must be >= 4mm and <= 8 mm by visual estimate.
  • The patient must have a baseline serum creatinine of <= 5.0 mg/dl.

Exclusion criteria

  • Total occlusion of the renal artery.
  • Lesions which would require more than 2 stents.
  • Lesions which are in arteries to transplanted or bypassed kidneys.
  • Abdominal aortic aneurysm > 4.0 cm in diameter.
  • Patients with ASA classification >=4.

Treatment and study plan

Sirolimus-eluting Palmaz Genesis peripheral stent

Device

treatment of renal artery stenosis with a renal stent

Other names: Palmaz Genesis Stent

Primary outcomes

  1. assessment of the angiographical in-stent minimal lumen diameter

    Time frame: 6-months follow up

Secondary outcomes

  1. clinical primary patency

    Time frame: discharge, 1, 6 and 12 months post-procedure

  2. procedural success

    Time frame: post-procedure

  3. worsening renal function

    Time frame: 30 days, 6 months, 12 months

  4. change in blood pressure measurement

    Time frame: 30 days, 6 months, 12 months

  5. significant embolic events causing end-organ damage

    Time frame: 30 days, 6 months, and 12 months

Sponsors and collaborators

Lead sponsor

Cordis US Corp.

Industry

Registry information

Official study title

Palmaz Genesis Peripheral Stainless Steel Balloon Expandable Stent, Comparing a Sirolimus Coated Versus an Uncoated Stent in REnal Artery Treatment.

Acronym: GREAT

Important dates

Study start
2001
Primary completion
2002
Study completion
2005
First posted
Oct 10, 2005
Registry last updated
Aug 6, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.